申请人:Goldstein Solo
公开号:US20070027191A1
公开(公告)日:2007-02-01
A compound selected from those of formula (I):
wherein: n represents an integer from 1 to 6 inclusive,
R
1
and R
2
represent a hydrogen atom, a (C
1
-C
6
)alkyl group or an aryl-(C
1
-C
6
)alkyl group,
R
3
and R
4
represent a hydrogen atom or a (C
1
-C
6
)alkyl group,
R
5
and R
6
represent a hydrogen atom, or a (C
1
-C
6
)alkyl, halogen, hydroxy, (C
1
-C
6
)alkoxy, cyano, nitro, (C
2
-C
6
)acyl, (C
1
-C
6
)alkoxycarbonyl, (C
1
-C
6
)trihaloalkyl, (C
1
-C
6
)trihaloalkoxy or optionally substituted amino group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of α4β2 receptors.
从以下公式(I)中选择的化合物:其中:n代表从1到6的整数,R1和R2代表氢原子,(C1-C6)烷基或芳基-(C1-C6)烷基,R3和R4代表氢原子或(C1-C6)烷基,R5和R6代表氢原子,或(C1-C6)烷基,卤素,羟基,(C1-C6)烷氧基,氰基,硝基,(C2-C6)酰基,(C1-C6)烷氧羰基,(C1-C6)三卤代烷基,(C1-C6)三卤代烷氧基或可选择取代的氨基团,其对映体,异构体和与其制备的药学上可接受的酸或碱的额外盐。含有这些化合物的药品在治疗需要特定α4β2受体烟碱配体的病症中非常有用。